Open AccessMolecular studies and therapeutic targeting of Kaposi’s sarcoma herpesvirus (KSHV/HHV-8) oncogenesis
Author(s) -
Enrique A. Mesri,
Lucas E. Cavallin,
Brittany M. Ashlock,
Howard J. Leung,
Qi Ma,
Pascal J. GoldschmidtClermont
Publication year - 2013
Publication title -
immunologic research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.841
H-Index - 87
eISSN - 1559-0755
pISSN - 0257-277X
DOI - 10.1007/s12026-013-8458-z
Subject(s) - primary effusion lymphoma , carcinogenesis , kaposi's sarcoma associated herpesvirus , lymphoma , viral oncogene , cancer research , lytic cycle , biology , oncogene , virology , gammaherpesvirinae , sarcoma , immunology , virus , medicine , cancer , herpesviridae , cell cycle , pathology , viral disease , genetics
Kaposi's sarcoma herpesvirus or human herpesvirus-8 (KSHV/HHV-8) is the etiological agent of Kaposi's sarcoma (KS), an AIDS-defining angioproliferative neoplasm that continues to be a major global health problem and, of primary effusion lymphoma (PEL), a rare incurable B-cell lymphoma. This review describes the research from our laboratory and its collaborators to uncover molecular mechanisms of viral oncogenesis in order to develop new pathogenesis-based therapies to the KSHV-induced AIDS malignancies KS and PEL. They include the discovery of the viral angiogenic oncogene G protein-coupled receptor (vGPCR), the development of mouse models of KSHV and oxidative stress-induced KS, the identification of the role of Rac1-induced ROS in viral oncogenesis of KS and the development of novel therapeutic approaches able to target both latent and lytic oncogenic KSHV infection.